Voyager Therapeutics, Inc.VYGREarnings & Financial Report
Voyager Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing AAV gene therapies for severe neurological diseases including Parkinson's, ALS, and rare monogenic CNS disorders. It operates mainly in the U.S., partnering with global biopharma companies to advance its treatment pipeline for underserved patient populations.
Revenue
$29.6M
Gross Profit
N/A
Operating Profit
$-15.0M
Net Profit
$-10.1M
Gross Margin
N/A
Operating Margin
-50.8%
Net Margin
-34.3%
YoY Growth
509.5%
EPS
$-0.18
Voyager Therapeutics, Inc. Q2 FY2024 Financial Summary
Voyager Therapeutics, Inc. reported revenue of $29.6M (up 509.5% YoY) for Q2 FY2024, with a net profit of $-10.1M (up 54.3% YoY) (-34.3% margin).
Key Financial Metrics
| Total Revenue | $29.6M |
|---|---|
| Net Profit | $-10.1M |
| Gross Margin | N/A |
| Operating Margin | -50.8% |
| Report Period | Q2 FY2024 |
Voyager Therapeutics, Inc. Annual Revenue by Year
Voyager Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $40.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $40.4M |
| 2024 | $80.0M |
Voyager Therapeutics, Inc. Quarterly Revenue & Net Profit History
Voyager Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $15.3M | +144.3% | N/A | N/A |
| Q3 FY2025 | $13.4M | -45.7% | $-27.9M | -208.7% |
| Q2 FY2025 | $5.2M | -82.4% | $-33.4M | -642.0% |
| Q1 FY2025 | $6.5M | -66.8% | $-31.0M | -479.2% |
| Q4 FY2024 | $6.3M | -93.0% | N/A | N/A |
| Q3 FY2024 | $24.6M | +433.8% | $-9.0M | -36.7% |
| Q2 FY2024 | $29.6M | +509.5% | $-10.1M | -34.3% |
| Q1 FY2024 | $19.5M | -87.0% | $-11.3M | -58.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $29.6M | $24.6M | $6.3M | $6.5M | $5.2M | $13.4M | $15.3M |
| YoY Growth | -87.0% | 509.5% | 433.8% | -93.0% | -66.8% | -82.4% | -45.7% | 144.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $469.6M | $436.2M | $426.0M | $393.1M | $353.2M | $322.1M | $288.3M | $252.3M |
| Liabilities | $128.7M | $100.8M | $95.7M | $93.3M | $80.5M | $78.2M | $68.5M | $56.2M |
| Equity | $340.9M | $335.4M | $330.3M | $299.8M | $272.7M | $243.9M | $219.8M | $196.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $58.8M | $-31.6M | $-28.0M | $-15.3M | $-37.9M | $-33.3M | $-31.0M | $-132.5M |